Pfizer Inc. $PFE Holdings Lifted by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. grew its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 3.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,501,243 shares of the biopharmaceutical company’s stock after acquiring an additional 45,592 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in Pfizer were worth $42,815,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Bank of America Corp DE purchased a new position in Pfizer in the second quarter worth about $1,049,602,000. BlackRock Inc. lifted its holdings in Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after acquiring an additional 31,412,883 shares during the period. Nykredit A S purchased a new position in shares of Pfizer in the second quarter worth approximately $205,774,000. Assenagon Asset Management S.A. boosted its stake in shares of Pfizer by 96.0% during the 2nd quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock worth $286,609,000 after acquiring an additional 5,829,204 shares during the last quarter. Finally, State Street Corp grew its holdings in Pfizer by 1.8% during the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after purchasing an additional 5,501,032 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on PFE. Argus set a $40.00 price objective on shares of Pfizer in a research note on Wednesday, November 4th. Weiss Ratings upgraded Pfizer from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, November 9th. Citigroup lifted their target price on Pfizer from $27.00 to $30.00 and gave the company a “neutral” rating in a research note on Wednesday, November 4th. FBN Securities set a $34.00 price target on Pfizer in a report on Friday, November 6th. Finally, Royal Bank Of Canada upped their price target on Pfizer from $25.00 to $28.00 and gave the stock a “sector perform” rating in a research note on Wednesday, November 4th. Six research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $30.32.

Get Our Latest Stock Report on PFE

Trending Headlines about Pfizer

Investors following PFE have been watching these headlines:

  • Positive Sentiment: Pfizer’s agreement with Starna Therapeutics gives it rights outside Greater China to develop three in vivo CAR-T programs for autoimmune diseases. The deal expands Pfizer’s pipeline and could open a new avenue for growth beyond its existing products. Reuters article
  • Positive Sentiment: Pfizer is scheduled to pay its 352nd consecutive quarterly dividend on Dec. 7, a long-running payout that may appeal to income-focused investors, though it is not a new increase. Dividend article
  • Negative Sentiment: The Starna deal carries up to $2.63 billion in potential payments, including $330 million upfront. Because the three programs are still pre-IND, they are years from possible commercialization and face substantial development risk; the upfront cost may help explain near-term investor caution. BioPharma Dive article

Pfizer Trading Down 1.8%

Shares of Pfizer stock opened at $27.57 on Friday. Pfizer Inc. has a twelve month low of $23.62 and a twelve month high of $31.44. The company has a quick ratio of 1.10, a current ratio of 1.42 and a debt-to-equity ratio of 0.67. The business has a 50-day moving average price of $28.83 and a 200-day moving average price of $27.02. The firm has a market cap of $157.12 billion, a price-to-earnings ratio of 39.38, a PEG ratio of 1.84 and a beta of 0.31.

Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. The company had revenue of $16.58 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the previous year, the business earned $0.87 earnings per share. The firm’s revenue for the quarter was down .4% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 3.04 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio is currently 245.71%.

Pfizer Profile

(Free Report)

Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.

Featured Stories

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.